Soluble klotho and mortality: The Ludwigshafen Risk and Cardiovascular Health Study
- 1 October 2015
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 242 (2) , 483-489
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- A Decreased Level of Serum Soluble Klotho Is an Independent Biomarker Associated with Arterial Stiffness in Patients with Chronic Kidney DiseasePLOS ONE, 2013
- Fibroblast Growth Factor-23 and Death, Heart Failure, and Cardiovascular Events in Community-Living IndividualsJACC, 2012
- FGF23 induces left ventricular hypertrophyJournal of Clinical Investigation, 2011
- The phosphatonin fibroblast growth factor 23 links calcium–phosphate metabolism with left-ventricular dysfunction and atrial fibrillationEuropean Heart Journal, 2011
- Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart diseaseAmerican Heart Journal, 2011
- Klotho Deficiency Causes Vascular Calcification in Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2011
- Comparative Performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study Equations for Estimating GFR Levels Above 60 mL/min/1.73 m2American Journal of Kidney Diseases, 2010
- Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjectsBiochemical and Biophysical Research Communications, 2010
- Klotho converts canonical FGF receptor into a specific receptor for FGF23Nature, 2006
- Suppression of Aging in Mice by the Hormone KlothoScience, 2005